Research Material

---

Overall, this guidance document aims to promote methods to increase the efficiency of efficacy detection in early-stage drug development trials (PoC/Phase II), preventing the discarding of new compounds from the companies’ pipeline too early. How To Reference To properly cite the ECNP COA Group Guide: Please acknowledge the "Outcomes Research in CNS Group and ECNP TWG Clinical Outcomes in Early-phase Clinical Trials. Clinical Outcomes Assessment Selection - Practical Guidance in Neuroscience Drug Development. Version 3, October 19th, 2022.”